{
    "Trade/Device Name(s)": [
        "Dexcom Pro Q Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K182405",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QDL"
    ],
    "Summary Letter Date": "November 2, 2018",
    "Summary Letter Received Date": "September 4, 2018",
    "Submission Date": "August 30, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom Pro Q Continuous Glucose Monitoring System"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Analyzer"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom Pro Q factory-calibrated continuous glucose monitoring system for retrospective glycemic variability analysis in persons age 2 and older.",
    "Indications for Use Summary": "Indicated for retrospective discovery, analysis, and interpretation of glycemic variability in persons age 2 years and older under healthcare professional supervision; aids in management of diseases or conditions related to glycemic control and interfaces with digitally connected devices.",
    "fda_folder": "Clinical Chemistry"
}